WASHINGTON — As Claire McCaskill fought to keep her U.S. Senate seat in Missouri a year ago, she made bipartisan outrage over drug prices a defining feature of her campaign.
It wasn’t enough. McCaskill lost her seat by 6 points, and Congress lost one of the pharmaceutical industry’s most unabashed critics. But McCaskill got some shots in along the way, likening drug company lobbying to a magical “fairy dust” that makes legislation disappear and telling voters in a television ad that “pharmaceutical companies are using the law to feed their greed.”
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- Online intelligence briefings
- Frequent opportunities to engage with veteran beat reporters and industry experts
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author
